The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• NUT carcinoma (NC) is a rare, aggressive cancer with poor prognosis.
• Current treatments like surgery, radiochemotherapy, and targeted therapies offer limited disease control.
• There is a critical need for novel therapeutic strategies for NC.

Purpose of the Study:

• To evaluate the oncolytic efficacy and replication of the recombinant oncolytic virus VSV-GP in human NC cell lines.
• To investigate potential mechanisms of resistance to VSV-GP in NC.
• To explore the potential of VSV-GP as a virotherapy for NC.

Main Methods:

• Transmission electron microscopy to visualize the VSV-GP replication cycle.
• Viability assays, xCELLigence, RT-qPCR, TCID50, and FACS analysis to assess oncolytic efficacy and replication kinetics.
• Exploration of resistance mechanisms in seven human NC cell lines.

Main Results:

• VSV-GP demonstrated significant oncolysis, apoptosis, and high replication in five out of seven NC cell lines.
• The viral entry receptor, α-dystroglycan, was equally expressed in permissive and resistant cell lines.
• VSV-GP infection suppressed intrinsic interferon-β synthesis, but intracellular signaling remained functional.

Conclusions:

• VSV-GP exhibits promising oncolytic activity against a majority of human NC cell lines.
• Understanding resistance mechanisms, such as interferon response, is crucial for optimizing VSV-GP therapy.
• Further research into virus-induced immunogenicity and resistance could lead to effective combination treatments for NC patients.